Understanding VTE Risk in Ambulatory Cancer Patients: Just Beginning to Scratch the Surface

Top Stories of 2009. 2010 Jan 1

Dr. David Henry is Clinical Professor of Medicine, Pennsylvania Hospital. View profile. 1. In your view, which development that occurred in 2009 could have the most significant impact on oncology practice?From my perspective, the top story of 2009 is not a new advance per se. Rather, the key development is oncologists’ increased awareness that ambulatory patients with cancer who are treated with chemotherapy are at a markedly elevated risk of experiencing a venous thromboembolism (VTE). Regardless...

NOT A MEMBER?

Registration is FREE

  • Up-to-date oncology news
  • Journal article summaries
  • Commentaries and interviews
  • Drug and interactions database
  • Chemotherapy regimens
  • Daily e-newsletters

 

Editors' Choice

Everolimus Plus Tamoxifen Improves Survival in Metastatic Breast Cancer

Meet Our Experts

Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
  • Forgot your password?
    Not a member? Free registration